Press Release FeedGet the RSS feed
Menu

GlobeNewswire

Tessera Therapeutics to Present New Preclinical Data Supporting its In Vivo Sickle Cell Disease Program and In Vivo CAR-T Applications at the 68th American Society of Hematology Annual Meeting

GlobeNewswire

November 04, 2026 11:06 ET

| Source:

Tessera Therapeutics

SOMERVILLE, Mass., Nov. 04, 2026 -- Tessera Therapeutics, Inc. (“Tessera”), a clinical-stage biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that three presentations of new preclinical data will be presented at the upcoming 68th American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, Louisiana, December 12 – 15, 2026.

Details of Tessera’s 68th ASH Annual Meeting presentations are as follows:

Oral presentations:

  • Title: Targeted LNP delivery of a Gene Writer in vivo enables generation of functional CAR-T cells in non-human primates
    Publication Number: 831
    Session: CAR T-cell Therapies: Basic and Translational: Engineering CAR-T Cell Fitness, Persistence, and Safety
    Presenter: Alberto De Iaco, Ph.D. 
    Date and Time: December 14, 2026, 11:00 a.m. – 11:15 a.m. CST
    Location: MCCNO, Room 353-355
  • Title: Single-dose in vivo HBB gene correction achieves durable editing of long-term hematopoietic stem cells and corrects sickle cell disease phenotypes
    Publication Number: 950
    Session: Gene Therapies: Beyond Transplant: The Expanding Role of Gene Therapy in Hematology
    Presenter: Giulia Schiroli, Ph.D. 
    Date and Time: December 14, 2026, 2:45 p.m. – 3:00 p.m. CST
    Location: MCCNO, Room 388-390

Poster presentation:

  • Title: Genome editing with all-RNA targeted lipid nanoparticles enables in vivo editing of hematopoietic stem cells for sickle cell disease and T cells for CAR-T applications
    Publication Number: 2547
    Session: Gene Therapies: Poster I
    Presenter: Mohit Gupta, Ph.D. 
    Date and Time: December 12, 2026, 5:30 p.m. – 7:30 p.m. CST
    Location: Ernest N. Morial Convention Center (MCCNO) – Hall F


About Tessera Therapeutics

Tessera Therapeutics is pioneering a new approach to genome engineering through the development of its Gene Writing™ and delivery platforms, with the aim to unlock broad new therapeutic frontiers. Our Gene Writing platform is designed to write therapeutic messages into the genome by efficiently changing single or multiple DNA base pairs, precisely correcting insertions and deletions, or adding exon-length sequences and whole genes. Our proprietary lipid nanoparticle delivery platform is designed to enable the in vivo delivery of RNA to targeted cell types. We believe our Gene Writing and delivery platforms will enable transformative genetic medicines to not only cure diseases that arise from errors in a single gene, but also modify inherited risk factors for common diseases and create engineered cells to treat cancer and potentially autoimmune and other diseases. Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability.

For more information about Tessera, please visit www.tesseratherapeutics.com.

Contact

Jonathan Pappas
LifeSci Communications, LLC
[email protected]

  1. AIJames Altucher, Tech Investor BaltimoreFrom 25 Launches a Year to 456. A New Free Presentation Reveals What Elon Musk Plans to Launch Next.SpaceX wants approval to fly Starship nearly every day from South Texas. James Altucher says Musk is already “TWO decades ahead” of his rivals in the race to put AI in orbit.
  2. Vereigen Media Publishes Modern Buying Committee Report, Highlighting Growing Complexity in B2B PurchasingAccording to this Modern Buying Committee Report, the total size of B2B buying committees grew from 5.4 stakeholders in 2015 to 6.8 by 2025.
  3. AIPanoPano AI Launches Drone Partner Program to Connect Wildfire Detection, Real Time Operating Picture, and Aerial ResponsePano AI Launches Drone Partner Program to Connect Wildfire Detection, Real Time Operating Picture, and Aerial Response
  4. EnergyDEADLINE ALERT for Honeywell Aerospace, Inc. (HONA) and Tigo Energy, Inc. (TYGO): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class ActionsInvestors in Honeywell Aerospace, Inc. and Tigo Energy, Inc. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions
  5. HealthcarePacific Health Care Organization, Inc. Reports its Third Quarter 2026 Financial ResultsPacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) filed yesterday with the Securities and Exchange Commission (the “SEC”) its quarterly report on Form 10-Q announcing its financial results for the quarter ended September 30, 2026.
  6. BankingDEADLINE ALERT for Gildan Activewear Inc. (GIL), D-Wave Quantum, Inc. (QBTS), and Bank Of America Corporation (BAC): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class ActionsInvestors in Gildan Activewear Inc., D-Wave Quantum, Inc., and Bank Of America Corporation have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions